EcoDrugPlus

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSOMYG00000015307
Gene Symbol: MKNK2B
1 Cross references
202 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2b

Ensembl ID : ENSOMYG00000009233
Gene Symbol: MKNK2B
1 Cross references
202 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSOMYG00000000121
Gene Symbol: MCL1B
1 Cross references
153 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member B

Ensembl ID : ENSOMYG00000011666
Gene Symbol: MCL1B
1 Cross references
152 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSOMYG00000074047
Gene Symbol: MDM2
1 Cross references
281 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSOMYG00000039881
Gene Symbol: MDM2
1 Cross references
281 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000022348
Gene Symbol: MET
1 Cross references
200 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSOMYG00000017070
Gene Symbol: MET
2 Cross references
200 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog (S. Cerevisiae)

Ensembl ID : ENSOMYG00000034843
Gene Symbol: MLST8
1 Cross references
199 Possible Orthologues:

N-Acetylated Alpha-Linked Acidic Dipeptidase 2

Ensembl ID : ENSOMYG00000038041
Gene Symbol: NAALAD2
2 Cross references
340 Possible Orthologues:

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSOMYG00000023536
Gene Symbol: NQO1
1 Cross references
179 Possible Orthologues:

Nad(P)h Dehydrogenase, Quinone 1

Ensembl ID : ENSOMYG00000026613
Gene Symbol: NQO1
1 Cross references
179 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).